$0.01
(Market cap
$6 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-12
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
10,735,649
10 Years Aggregate
CFO
$-35.35 Mln
EBITDA
$-75.53 Mln
Net Profit
$-75.30 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PharmaCyte Biotech Inc (PMCB)
| -31.6 | -14.1 | -34.1 | -46.9 | -41.6 | -32.1 | -38.1 |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
PharmaCyte Biotech Inc (PMCB)
| -53.9 | -27.1 | -26.3 | 17.2 | -75.1 | -83.5 | 9.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PharmaCyte Biotech Inc (PMCB)
|
0.5 | 5.5 | 0.0 | -19.4 | -- | -45.6 | -- | 0.2 |
| 248.9 | 53,134.3 | 254,248.0 | 1,714.0 | 1.0 | -60.5 | 32.5 | 16.1 | |
| 1.3 | 67.6 | 0.1 | -33.0 | -22,344.0 | -65.7 | -- | 0.9 | |
| 6.2 | 80.2 | 182.6 | 5.1 | 3.1 | 14.9 | 15.9 | 2.4 | |
| 38.5 | 1,529.5 | 1,518.1 | 99.7 | 12.2 | 29.7 | 14.9 | 3.8 | |
| 4.5 | 631.5 | 915.5 | -122.6 | -6.0 | -6.6 | -- | 0.4 |
Shareholding Pattern
View DetailsAbout PharmaCyte Biotech Inc (PMCB)
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based... on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Read more
-
Interim CEO, President & Director
Mr. Joshua N. Silverman
-
Interim CEO, President & Director
Mr. Joshua N. Silverman
-
Headquarters
Las Vegas, NV
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for PharmaCyte Biotech Inc (PMCB)
What is the current share price of PharmaCyte Biotech Inc (PMCB) Today?
The share price of PharmaCyte Biotech Inc (PMCB) is $0.49 (NASDAQ) as of 03-Sep-2026 13:38 EDT. PharmaCyte Biotech Inc (PMCB) has given a return of -41.56% in the last 3 years.
What is the current PB & PE ratio of PharmaCyte Biotech Inc (PMCB)?
Since, TTM earnings of PharmaCyte Biotech Inc (PMCB) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
-- |
-- |
2025 |
-- |
-- |
2024 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
What is the 52 Week High and Low of PharmaCyte Biotech Inc (PMCB)?
The 52-week high and low of PharmaCyte Biotech Inc (PMCB) are Rs 1.51 and Rs 0.47 as of 04-Sep-2026.
What is the market cap of PharmaCyte Biotech Inc (PMCB)?
PharmaCyte Biotech Inc (PMCB) has a market capitalisation of $ 6 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in PharmaCyte Biotech Inc (PMCB)?
Before investing in PharmaCyte Biotech Inc (PMCB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.